Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from InMed Pharmaceuticals ( (INM) ) is now available.
InMed Pharmaceuticals reported its fiscal year 2025 financial results, highlighting advancements in its INM-901 program targeting Alzheimer’s disease through multiple biological pathways. The company demonstrated significant progress in reducing neuroinflammation and improving cognitive function in preclinical studies, aligning with emerging themes in Alzheimer’s research. Additionally, InMed strengthened its financial position to support ongoing pharmaceutical developments into late 2026, positioning itself to contribute to the next generation of Alzheimer’s treatments.
The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Underperform.
InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs. The company is advancing its pharmaceutical drug development programs and operates a commercial segment through its wholly-owned subsidiary, BayMedica, LLC.
Average Trading Volume: 1,868,697
Technical Sentiment Signal: Sell
Current Market Cap: $4.54M
For an in-depth examination of INM stock, go to TipRanks’ Overview page.